Contrave - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:46Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antidepressants]]
			[[Category:Opioid antagonists]]
			[[Category:Anorectics]]
			[[Category:Fixed-dose combinations]]

MDElliottMD: home-claude house-rule fix (terminology)

2026-05-23T04:50:58Z

home-claude house-rule fix (terminology)

← Older revision		Revision as of 04:50, 23 May 2026
Line 16:		Line 16:
	\| pregnancy = Contraindicated in pregnancy (FDA label).{{citation needed}}		\| pregnancy = Contraindicated in pregnancy (FDA label).{{citation needed}}
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US. '''Contraindicated''' in uncontrolled hypertension, seizure disorder, anorexia/bulimia, chronic opioid use (would precipitate withdrawal), and during/within 14 days of MAOI use. Carries '''Boxed Warning''' for suicidal thoughts and neuropsychiatric reactions (bupropion class effect)<ref name="contrave-label" />		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. '''Contraindicated''' in uncontrolled hypertension, seizure disorder, anorexia/bulimia, chronic opioid use (would precipitate withdrawal), and during/within 14 days of MAOI use. Carries '''Boxed Warning''' for suicidal thoughts and neuropsychiatric reactions (bupropion class effect)<ref name="contrave-label" />
	\| mechanism = <vote slug="contrave-mech-claim">Bupropion inhibits norepinephrine and dopamine reuptake, activating POMC neurons in the hypothalamus to release α-MSH (suppressing appetite) and β-endorphin (which would normally feed back to inhibit POMC). Naltrexone blocks the β-endorphin autoinhibition, sustaining the appetite-suppressing POMC activity. The combination achieves greater weight loss than either component alone.</vote> Modest absolute weight loss (~5% from baseline at 1 year) versus placebo. ~~Drug-interaction~~ profile includes CYP2D6 inhibition (bupropion), so dose-adjustment for tricyclic antidepressants, β-blockers metabolized by 2D6, and certain ~~antipsychotics~~ is warranted<ref name="contrave-label" />.		\| mechanism = <vote slug="contrave-mech-claim">Bupropion inhibits norepinephrine and dopamine reuptake, activating POMC neurons in the hypothalamus to release α-MSH (suppressing appetite) and β-endorphin (which would normally feed back to inhibit POMC). Naltrexone blocks the β-endorphin autoinhibition, sustaining the appetite-suppressing POMC activity. The combination achieves greater weight loss than either component alone.</vote> Modest absolute weight loss (~5% from baseline at 1 year) versus placebo. Interaction profile includes CYP2D6 inhibition (bupropion), so dose-adjustment for tricyclic antidepressants, β-blockers metabolized by 2D6, and certain neuroleptics is warranted<ref name="contrave-label" />.
	}}		}}

	== References ==		== References ==
	<references />		<references />

MDElliottMD: parser-claude batch MedTemplate pre-fill, mind-medicine combination

2026-05-23T04:44:11Z

parser-claude batch MedTemplate pre-fill, mind-medicine combination

New page

{{MedTemplate
| generic = Bupropion / Naltrexone
| brand = Contrave (US), Mysimba (EU)
| structure =
| classes = [[:Category:Antidepressants|Antidepressant (bupropion, atypical)]], [[:Category:Opioid_antagonists|Opioid antagonist (naltrexone)]], [[:Category:Anorectics|Anorectic (weight-loss agent)]], [[:Category:Fixed-dose_combinations|Fixed-dose combination]]
| uses = <vote slug="obesity-treatment-use">Chronic weight management adjunct in obesity (BMI ≥30, or ≥27 with risk factors)</vote>
| starting_dose = Week 1: 1 tablet (8/90 mg) PO morning; week 2: 1 tablet AM + 1 PM; week 3: 2 AM + 1 PM; week 4 onward: 2 AM + 2 PM (32 mg naltrexone / 360 mg bupropion/d)
| preparations = 8 mg naltrexone / 90 mg bupropion ER tablets (titration-pack design)
| fda_max = 32 mg naltrexone / 360 mg bupropion per day
| pill_id =
| routes = Oral
| onset = Modest appetite suppression within weeks; weight loss over months
| duration = 12 hours (BID dosing required)
| halflife = Naltrexone ~4 hours (6β-naltrexol metabolite ~13 hours); bupropion ~21 hours<ref name="contrave-label">FDA Prescribing Information, Contrave (naltrexone HCl / bupropion HCl), Currax Pharmaceuticals, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/200063s011lbl.pdf</ref>
| bioavailability = Naltrexone ~5% (oral, extensive first-pass to 6β-naltrexol); bupropion ER ~87%<ref name="contrave-label" />
| pregnancy = Contraindicated in pregnancy (FDA label).{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated''' in uncontrolled hypertension, seizure disorder, anorexia/bulimia, chronic opioid use (would precipitate withdrawal), and during/within 14 days of MAOI use. Carries '''Boxed Warning''' for suicidal thoughts and neuropsychiatric reactions (bupropion class effect)<ref name="contrave-label" />
| mechanism = <vote slug="contrave-mech-claim">Bupropion inhibits norepinephrine and dopamine reuptake, activating POMC neurons in the hypothalamus to release α-MSH (suppressing appetite) and β-endorphin (which would normally feed back to inhibit POMC). Naltrexone blocks the β-endorphin autoinhibition, sustaining the appetite-suppressing POMC activity. The combination achieves greater weight loss than either component alone.</vote> Modest absolute weight loss (~5% from baseline at 1 year) versus placebo. Drug-interaction profile includes CYP2D6 inhibition (bupropion), so dose-adjustment for tricyclic antidepressants, β-blockers metabolized by 2D6, and certain antipsychotics is warranted<ref name="contrave-label" />.
}}

== References ==
<references />